Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
07:00am, Wednesday, 04'th Sep 2024
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
07:00am, Wednesday, 21'st Aug 2024
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
12:06pm, Thursday, 15'th Aug 2024
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity.
NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDA
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
03:45pm, Tuesday, 06'th Aug 2024
Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company's SG&A and R&D expenses significantly increased, leading to wider net losse
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
12:30pm, Monday, 05'th Aug 2024
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
Why Axsome Therapeutics Stock Is Sinking Today
12:15pm, Monday, 05'th Aug 2024
Axsome's Q2 revenue beat estimates, but the company posted a wider net loss than expected. The primary culprit behind the disappointing bottom line were noncash charges of $26 million.
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
11:20am, Monday, 05'th Aug 2024
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick
Does Axsome (AXSM) Have the Potential to Rally 48.44% as Wall Street Analysts Expect?
11:01am, Monday, 05'th Aug 2024
The mean of analysts' price targets for Axsome (AXSM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
09:11am, Monday, 05'th Aug 2024
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1 per share a year ago.
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07:00am, Monday, 05'th Aug 2024
Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 20
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:06am, Monday, 29'th Jul 2024
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks to Bet On Bright Industry Prospects
10:45am, Monday, 29'th Jul 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, S
7 Biotech Stocks to Keep on Your Clinical Radar
02:57pm, Tuesday, 23'rd Jul 2024
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be rel
Axsome Therapeutics: Lots Of Moving Parts
04:06am, Tuesday, 23'rd Jul 2024
Today, we circle back to mid-cap biopharma Axsome Therapeutics, which has multiple potential catalysts on the horizon. The company has two approved products on the market and the potential to have six
